Statins and Portal Hypertension: A Systematic Review and Meta-analysis of Randomized Controlled Trials

被引：1

作者：

Jamialahmadi, Tannaz ^{[1
,2
]}

Reiner, Zeljko ^{[3
]}

Riahi, Maryam Matbou ^{[2
]}

Emami, Seyed Ahmad ^{[4
]}

Tayarani-Najaran, Zahra ^{[5
,6
]}

Salehabadi, Sepideh ^{[2
]}

Kesharwani, Prashant ^{[7
,8
]}

Al-Rasadi, Khalid ^{[9
]}

Sahebkar, Amirhossein ^{[2
,10
]}

机构：

[1] Mashhad Univ Med Sci, Int UNESCO Ctr Hlth Related Basic Sci & Human Nut, Mashhad, Iran

[2] Mashhad Univ Med Sci, Appl Biomed Res Ctr, Mashhad, Iran

[3] Univ Zagreb, Univ Hosp Ctr Zagreb, Dept Internal Med, Kispaticeva 12, Zagreb, Croatia

[4] Mashhad Univ Med Sci, Dept Tradit Pharm, Mashhad, Iran

[5] Mashhad Univ Med Sci, Pharmaceut Technol Inst, Targeted Drug Delivery Res Ctr, Mashhad, Iran

[6] Mashhad Univ Med Sci, Med Toxicol Res Ctr, Mashhad, Iran

[7] Jamia Hamdard, Sch Pharmaceut Educ & Res, Dept Pharmaceut, New Delhi 110062, India

[8] Saveetha Inst Med & Tech Sci, Saveetha Dent Coll, Ctr Transdisciplinary Res, Dept Pharmacol, Chennai 600077, India

[9] Sultan Qaboos Univ, Med Res Ctr, POB 373, Muscat, Oman

[10] Mashhad Univ Med Sci, Sch Pharm, Dept Biotechnol, Mashhad, Iran

来源：

CURRENT MEDICINAL CHEMISTRY | 2025年 / 32卷 / 07期

关键词：

Statins; portal hypertension; chronic liver disease; Rho-kinase activity; nitric oxide; HMG-CoA; NITRIC-OXIDE PRODUCTION; THERAPY; SIMVASTATIN; CIRRHOSIS; PREVENTION; LIVER; ATORVASTATIN; PLACEBO; KLF2; DECOMPENSATION;

D O I：

10.2174/0929867331666230918114451

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Background Statins are primarily used to decrease elevated LDL-cholesterol and thus prevent atherosclerotic cardiovascular disease. Portal hypertension is one of the most important complications of chronic liver disease. Several studies indicated that statins might be beneficial for portal hypertension as well but there is still no clear answer whether this is true or not.Methods A literature search of the major databases was performed to find eligible randomized controlled trials (RCTs) analyzing the effect of statins on portal hypertension from inception to February 5th, 2021. Six RCTs with 442 patients who received statin or statin plus carvedilol were finally included. Meta-analysis was performed using the Comprehensive Meta-Analysis V2 software.Results Reduction of portal hypertension after statin treatment was not significant (WMD: -0.494, 95% CI: -1.239, 0.252, p=0.194; I2:0%). The reduction of portal hypertension was robust in the leave-one-out sensitivity analysis.Conclusion Treatment with statins did not decrease significantly portal hypertension.

引用

页码：1323 / 1332

页数：10

共 62 条

[1] Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis [J].

Abraldes, Juan G. ;

Villanueva, Candid ;

Aracil, Carles ;

Turnes, Juan ;

Hernandez-Guerra, Manuel ;

Genesca, Joan ;

Rodriguez, Manuel ;

Castellote, Jose ;

Carlos Garcia-Pagan, Juan ;

Torres, Ferran ;

Luis Calleja, Jose ;

Albillos, Agustin ;

Bosch, Jaime .

GASTROENTEROLOGY, 2016, 150 (05) :1160-+

[2] Simvastatin Lowers Portal Pressure in Patients With Cirrhosis and Portal Hypertension: A Randomized Controlled Trial [J].

Abraldes, Juan G. ;

Albillos, Agustin ;

Banares, Rafael ;

Turnes, Juan ;

Gonzalez, Rosario ;

Garcia-Pagan, Juan Carlos ;

Bosch, Jaime .

GASTROENTEROLOGY, 2009, 136 (05) :1651-1658

[3]

Alvarado-Tapias E., Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with portal hypertension and no-response to beta-blockers: a doubleblind randomized trial

[4] The role of statins in lung cancer [J].

Amin, Fatemeh ;

Fathi, Farzaneh ;

Reiner, Zeljko ;

Banach, Maciej ;

Sahebkar, Amirhossein .

ARCHIVES OF MEDICAL SCIENCE, 2022, 18 (01) :141-152

[5] Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study [J].

Ayada, Ibrahim ;

van Kleef, Laurens A. ;

Zhang, Huai ;

Liu, Kuan ;

Li, Pengfei ;

Abozaid, Yasir J. ;

Lavrijsen, Marla ;

Janssen, Harry L. A. ;

van der Laan, Luc J. W. ;

Ghanbari, Mohsen ;

Peppelenbosch, Maikel P. ;

Zheng, Ming-Hua ;

de Knegt, Robert J. ;

Pan, Qiuwei .

EBIOMEDICINE, 2023, 87

[6] Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ageing: Molecular mechanisms [J].

Bahrami, Afsane ;

Bo, Simona ;

Jamialahmadi, Tannaz ;

Sahebkar, Amirhossein .

AGEING RESEARCH REVIEWS, 2020, 58

[7] Effect of statins on toll-like receptors: a new insight to pleiotropic effects [J].

Bahrami, Afsane ;

Parsamanesh, Negin ;

Atkin, Stephen L. ;

Banach, Maciej ;

Sahebkar, Amirhossein .

PHARMACOLOGICAL RESEARCH, 2018, 135 :230-238

[8] 2022: the year in cardiovascular disease - the year of upfront lipid lowering combination therapy [J].

Banach, Maciej ;

Reiner, Zeljko ;

Cicero, Arrigo F. G. ;

Sabouret, Pierre ;

Viigimaa, Margus ;

Sahebkar, Amirhossein ;

Postadzhiyan, Arman ;

Gaita, Dan ;

Pella, Daniel ;

Penson, Peter E. .

ARCHIVES OF MEDICAL SCIENCE, 2022, 18 (06) :1429-1434

[9] Statin therapy and plasma coenzyme Q10 concentrations-A systematic review and meta-analysis of placebo-controlled trials [J].

Banach, Maciej ;

Serban, Corina ;

Ursoniu, Sorin ;

Rysz, Jacek ;

Muntner, Paul ;

Toth, Peter P. ;

Jones, Steven R. ;

Rizzo, Manfredi ;

Glasser, Stephen P. ;

Watts, Gerald F. ;

Blumenthal, Roger S. ;

Lip, Gregory Y. H. ;

Mikhailidis, Dimitri P. ;

Sahebkar, Amirhossein .

PHARMACOLOGICAL RESEARCH, 2015, 99 :329-336

[10] Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study [J].

Bishnu, Saptarshi ;

Ahammed, S. K. M. ;

Sarkar, Avik ;

Hembram, Jabaranjan ;

Chatterjee, Saswata ;

Das, Kshaunish ;

Dhali, Gopal K. ;

Chowdhury, Abhijit ;

Das, Kausik .

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2018, 30 (01) :54-59

← 1 2 3 4 5 6 7 →